Profusa (PFSA)

Profusa’s technology is aimed at measuring key biochemical signals and transmitting that data for use by patients, clinicians, and researchers. Its most developed commercial platform is Lumee Oxygen, which has been introduced in the European Union. The system is designed to monitor tissue oxygen levels at specific areas of interest over both acute and longer-term periods, giving healthcare providers additional information where blood flow and tissue viability are important.

Potential uses for Lumee Oxygen include peripheral artery disease, chronic wounds, and reconstructive surgery. In these settings, tissue oxygenation can help indicate whether circulation is adequate, whether a wound environment is improving, or whether repaired tissue is at risk. Profusa’s broader opportunity lies in combining implanted sensors with digital data transmission to support earlier intervention and more personalized medical decision-making.

As a development-stage healthcare company, Profusa operates in a highly regulated market where clinical validation, regulatory approvals, reimbursement, and physician adoption are central to its prospects. Its appeal to investors is tied to the possibility that long-lasting biosensors can create a new category of real-time health monitoring beyond conventional blood tests, imaging, or external devices.